Clarifying questions on restraint uses
Briefings on The Joint Commission, June 1, 2008
This is an excerpt from a member only article. To read the article in its entirety, please login or subscribe to Briefings on The Joint Commission.
Editor’s note: Sue Dill Calloway, RN, MSN, JD, director of hospital risk management for OHIC Insurance Company, The Doctor’s Company, in Columbus, OH, is the CMS corner lead contributor. Submit a topic idea to her by contacting BOJ Editor Matt Phillion at mphillion@hcpro.com.
I recently had the privilege of working with a hospital that had a visit from its state department of health regarding the CMS restraint and seclusion regulations. New regulations on restraint and seclusion took effect on January 8, 2007. The restraint and seclusion changes were published in the Federal Register, and the interpretive guidelines were released in April this year.
This is an excerpt from a member only article. To read the article in its entirety, please login or subscribe to Briefings on The Joint Commission.
Comments
0 comments on “Clarifying questions on restraint uses ”
Related Products
Most Popular
- Articles
-
- Featured blog post: Nurses face felony charges after reporting physician to the Texas Medical Board
- HIPAA Q&A: TPO disclosures to a business associate
- Q/A: Coding infusions to correct low potassium levels
- Topic: CMS, OESS post new security compliance review information, checklist
- What does case-mix index mean to you?
- The debate continues: Nurses who reported physician to the Texas Medical Board file federal appeal
- State medical board will hear unprofessional charges against OB-GYN
- Capturing all necessary codes for IUD insertion and removal can be challenging
- QA:Coding multiple initial infusions
- Major mobile operators to support free text alerts
- E-mailed
-
- Featured blog post: Nurses face felony charges after reporting physician to the Texas Medical Board
- Q/A: Coding infusions to correct low potassium levels
- Know criteria for coverage when podiatrists use Dermagraft® tissue substitute
- Note: Clarification of reference (non-patient) laboratory testing
- HIPAA Q&A: TPO disclosures to a business associate
- Get the facts on coding for non-biodegradeable drug delivery implants
- Facility E/M Levels, 2009 OPPS
- Do not separately report defibrillation
- Defining 'integral' for self-administered drugs is challenging
- Consider the big picture before querying physicians
- Searched
